Stocktoria
Valion Bio, Inc. VBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-11-11
Valion Bio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $780,000 | $1.2M | $1.8M | $1.3M |
| Gross profit | — | $2,000 | $287,000 | $299,000 | -$38,000 |
| R&D expense | $3.1M | $1.3M | $1.7M | $1.7M | $878,000 |
| SG&A expense | $4.8M | $3.2M | — | — | — |
| Operating income | -$7.9M | -$4.5M | -$8.2M | -$10.1M | -$5.6M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$8.9M | -$5.7M | -$8.2M | -$10.1M | -$8.5M |
| EPS (diluted) | — | $-19.68 | $-176.80 | $-104.32 | $-2.43 |
| Operating cash flow | -$7.0M | -$5.7M | -$8.5M | -$8.9M | -$5.6M |
| Free cash flow | -$7.0M | -$5.7M | -$8.6M | -$8.9M | — |
| Cash & equivalents | $12.6M | $2.0M | $3.4M | $3.5M | $13.0M |
| Inventory | $0 | $319,000 | $756,000 | $863,000 | $429,000 |
| Total assets | $31.6M | $2.8M | $5.2M | $5.9M | $15.0M |
| Total liabilities | $7.4M | $272,000 | $1.6M | $2.2M | $1.8M |
| Shareholders' equity | $16.8M | $2.5M | $3.6M | $3.6M | $13.3M |
Source: SEC EDGAR filings · CIK 0001787740 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.